April 09, 2014 16:15 ET
CALGARY, ALBERTA--(Marketwired - April 9, 2014) - Supreme Pharmaceuticals Inc. (the "Company") (TSX VENTURE:SL)(PINKSHEETS:SPRWF) notes that in respect to its prior press release on Friday April 4, 2014, the Company will be utilizing the full 7 business days to complete and conclude the due diligence period. This means that the Company will report news on Tuesday, April 15, 2014 with a final decision on the South Okanagan producing medical marijuana facility.
We apologize for the misperception from the prior press release that a decision would be made as of April 10, 2014.
The process thus far has been positive and the process is moving ahead smoothly.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This News Release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com. This News Release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Supreme Pharmaceuticals Inc.#772 Alastair Ross Technology Centre3553 - 31st Street NW, Calgary, Alberta, T2L 2K7Phone: (647) 340-6744Email: email@example.comWebsite: www.supremepharmaceuticals.com
See all RSS Newsfeeds